Dihydrobenzoxathiazepine Derivatives as AMPA Receptor Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mnemocognitive disorders and neurodegenerative diseases lack effective positive allosteric modulators for AMPA receptors, which are crucial for learning and memory processes.
Innovation Solution
Development of dihydrobenzoxathiazepine derivatives that act as powerful positive allosteric modulators of AMPA receptors, specifically compounds of formula (I) and their pharmaceutical compositions, which can be administered in various forms for oral, parenteral, or topical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mnemocognitive disorders are used, then existing therapeutic options are available, but effective positive allosteric modulators for AMPA receptors are lacking
Solution Approach 1:
The invention segments the therapeutic approach by developing specific dihydrobenzoxathiazepine derivative compounds that selectively target AMPA receptors, separating this mechanism from existing broad-spectrum treatments for mnemocognitive disorders
Solution Approach 2:
The invention changes the pharmacological parameter by introducing compounds with specific positive allosteric modulator properties at AMPA receptors, transforming the therapeutic landscape from lacking effective modulators to having potent, selective agents
2Reliability
If dihydrobenzoxathiazepine derivatives are developed as AMPA receptor modulators, then memory performance and neuronal excitability are improved, but the complexity of pharmaceutical development increases
Solution Approach 1:
The invention optimizes chemical parameters by defining specific structural variations of dihydrobenzoxathiazepine derivatives with different R1 groups, balancing potency with manageable pharmaceutical complexity
Solution Approach 2:
The invention creates a universal platform of compounds with formula (I) that can address multiple conditions including Alzheimer's disease, anxiety, and depressive syndromes through a common mechanism of AMPA receptor modulation
Data Source
AI summary
Compounds of formula (I): in which R1 represents a hydrogen atom, a heterocyclic group, cyano, alkoxycarbonyl, alkylsulfonylaminoalkyl, or N-hydroxycarboximidamide; their use as modulators of AMPA receptors.